Clinical Trial Update: A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pamiparib combined with abiraterone acetate as neoadjuvant treatment for prostate cancer is in early stages with unclear status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Pamiparib (pamiparib)

Snippet

Sponsor: Hongqian Guo | Conditions: Neoadjuvant Therapy | Phase 2 | Status: UNKNOWN